West Oak Capital LLC Has $2.43 Million Stake in Johnson & Johnson (NYSE:JNJ)

West Oak Capital LLC lessened its stake in Johnson & Johnson (NYSE:JNJ) by 0.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 18,812 shares of the company’s stock after selling 120 shares during the quarter. Johnson & Johnson comprises approximately 1.7% of West Oak Capital LLC’s holdings, making the stock its 5th biggest holding. West Oak Capital LLC’s holdings in Johnson & Johnson were worth $2,428,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the company. Legacy Capital Partners Inc. increased its stake in Johnson & Johnson by 1.6% during the 4th quarter. Legacy Capital Partners Inc. now owns 40,553 shares of the company’s stock worth $5,233,000 after buying an additional 625 shares during the period. Moody National Bank Trust Division increased its stake in Johnson & Johnson by 1.3% during the 4th quarter. Moody National Bank Trust Division now owns 210,859 shares of the company’s stock worth $27,212,000 after buying an additional 2,629 shares during the period. Clarus Wealth Advisors increased its stake in Johnson & Johnson by 9.1% during the 4th quarter. Clarus Wealth Advisors now owns 2,994 shares of the company’s stock worth $386,000 after buying an additional 250 shares during the period. Bath Savings Trust Co increased its stake in Johnson & Johnson by 5.8% during the 4th quarter. Bath Savings Trust Co now owns 38,335 shares of the company’s stock worth $4,948,000 after buying an additional 2,091 shares during the period. Finally, Silverleafe Capital Partners LLC purchased a new stake in Johnson & Johnson during the 4th quarter worth $298,000. 67.29% of the stock is currently owned by institutional investors and hedge funds.

Shares of JNJ stock traded up $0.54 during midday trading on Monday, reaching $136.52. 4,661,976 shares of the company were exchanged, compared to its average volume of 6,780,161. Johnson & Johnson has a 12 month low of $118.62 and a 12 month high of $148.99. The company has a market capitalization of $362.76 billion, a price-to-earnings ratio of 16.69, a price-to-earnings-growth ratio of 2.07 and a beta of 0.68. The company has a current ratio of 1.47, a quick ratio of 1.20 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, January 22nd. The company reported $1.97 EPS for the quarter, topping analysts’ consensus estimates of $1.95 by $0.02. Johnson & Johnson had a net margin of 18.75% and a return on equity of 35.63%. The company had revenue of $20.39 billion for the quarter, compared to the consensus estimate of $20.27 billion. During the same period in the previous year, the firm earned $1.74 EPS. Johnson & Johnson’s revenue was up 1.0% on a year-over-year basis. On average, equities research analysts predict that Johnson & Johnson will post 8.58 earnings per share for the current year.

Johnson & Johnson announced that its board has approved a share repurchase program on Monday, December 17th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the company to purchase up to 1.5% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board of directors believes its shares are undervalued.

Several research analysts have recently commented on the stock. Zacks Investment Research lowered shares of Johnson & Johnson from a “buy” rating to a “sell” rating in a report on Tuesday, December 18th. Citigroup lifted their price target on shares of Johnson & Johnson from $139.00 to $147.00 and gave the company a “neutral” rating in a report on Monday, February 25th. Morgan Stanley set a $140.00 target price on shares of Johnson & Johnson and gave the company a “hold” rating in a research note on Thursday, December 20th. Barclays reissued an “equal weight” rating and set a $135.00 target price (down from $137.00) on shares of Johnson & Johnson in a research note on Wednesday, January 23rd. Finally, Wells Fargo & Co reissued an “outperform” rating and set a $152.00 target price (down from $162.00) on shares of Johnson & Johnson in a research note on Monday, January 14th. Six equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $143.58.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.baseballdailydigest.com/news/2019/04/15/johnson-johnson-jnj-is-west-oak-capital-llcs-5th-largest-position.html.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: Why is the conference call important?

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.